PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2898111-7 1988 Cholecystokinin, angiotensin II, vasopressin, thyrotropin-releasing hormone and bombesin also stimulated [3H]IP1 production but were generally much weaker than BK. Tritium 106-108 arginine vasopressin Homo sapiens 33-44 2521556-2 1989 Binding of [3H]vasopressin to the solubilized fraction was rapid, specific, and saturable. Tritium 12-14 arginine vasopressin Homo sapiens 15-26 2557763-2 1989 [3H]Arginine vasopressin bound with affinity similar to that of [3H]oxytocin to both tissues (dissociation constant 1 to 2 nmol/L). Tritium 1-3 arginine vasopressin Homo sapiens 13-24 2557763-3 1989 The concentration of [3H]arginine vasopressin binding sites was high, particularly in decidua, but in all instances was about 50% to 60% of [3H]oxytocin binding. Tritium 22-24 arginine vasopressin Homo sapiens 34-45 2557763-5 1989 Analogs with selective antidiuretic activity (1-deamino-8-D-arginine vasopressin) showed drastically reduced affinity to [3H]oxytocin binding sites and relatively low but significantly higher affinity to [3H]arginine vasopressin binding sites. Tritium 122-124 arginine vasopressin Homo sapiens 69-80 2557763-5 1989 Analogs with selective antidiuretic activity (1-deamino-8-D-arginine vasopressin) showed drastically reduced affinity to [3H]oxytocin binding sites and relatively low but significantly higher affinity to [3H]arginine vasopressin binding sites. Tritium 205-207 arginine vasopressin Homo sapiens 69-80 2533288-3 1989 Binding studies using [3H]AVP demonstrated a decreased number of binding sites (Bmax) on platelets from patients with CRF compared to normal controls with no significant difference in affinity (Ka). Tritium 23-25 arginine vasopressin Homo sapiens 26-29 2548484-6 1989 Cholera toxin or forskolin also reduced the maximal specific binding, to intact WRK 1 cells, of both [3H][Arg8]vasopressin and the V1a antagonist [3H][beta-mercapto-beta,beta-cyclopentamethylenepropionic acid,O-methyl-Tyr2, Arg8]vasopressin. Tritium 102-104 arginine vasopressin Homo sapiens 111-122 2548484-6 1989 Cholera toxin or forskolin also reduced the maximal specific binding, to intact WRK 1 cells, of both [3H][Arg8]vasopressin and the V1a antagonist [3H][beta-mercapto-beta,beta-cyclopentamethylenepropionic acid,O-methyl-Tyr2, Arg8]vasopressin. Tritium 102-104 arginine vasopressin Homo sapiens 229-240 2529940-2 1989 Binding of tritium-labeled vasopressin ([3H]AVP) was measured in surface membranes (SM), microsomes (M), and a 100,000 g (60-min) microsomal supernatant fraction (S). Tritium 11-18 arginine vasopressin Homo sapiens 27-38 3109249-6 1987 A crude membrane preparation derived from bladders photolabeled with 4-N3-AVT contained 72 fmol of specific binding sites for tritium-labeled vasopressin per milligram protein, whereas nonphotolabeled controls had 136 fmol of specific binding sites per milligram protein. Tritium 126-133 arginine vasopressin Homo sapiens 142-153 3807642-3 1987 [3H]AVP binds to this soluble receptor with an equilibrium dissociation constant of 11.03 +/- 1.86 nM and a maximal number of binding sites = 288 +/- 66 fmol/mg protein while the corresponding values of the membrane-bound receptor are 1.62 +/- 0.21 nM and 237 +/- 38 fmol/mg of protein, respectively. Tritium 1-3 arginine vasopressin Homo sapiens 4-7 3490977-11 1986 Adrenaline also enhances the extent of [3H]5HT secretion induced by U46619, thrombin and vasopressin but fails to increase that induced by ADP in this aspirin-treated preparation. Tritium 40-42 arginine vasopressin Homo sapiens 89-100 3153472-2 1987 HPLC analysis of [3H]inositol-labeled cells indicated that AVP stimulated a rapid increase in inositol-1,4,5 trisphosphate (IP3), inositol-1,4 bisphosphate, and inositol-4 monophosphate levels. Tritium 18-20 arginine vasopressin Homo sapiens 59-62 3153472-6 1987 Therefore, [3H]AVP binding was determined in control and DEX-treated cells. Tritium 12-14 arginine vasopressin Homo sapiens 15-18 3425722-1 1987 High-performance liquid chromatography (HPLC) analysis revealed that [3,4,5-3H-Phe3,Arg8]vasopressin ([3H]AVP) was not degraded by isolated renal brush-border membranes or by a cortical lysosomal fraction in vitro; however, in the presence of 1 mM reduced glutathione, [3H]AVP was degraded by both preparations. Tritium 76-78 arginine vasopressin Homo sapiens 106-109 3425722-1 1987 High-performance liquid chromatography (HPLC) analysis revealed that [3,4,5-3H-Phe3,Arg8]vasopressin ([3H]AVP) was not degraded by isolated renal brush-border membranes or by a cortical lysosomal fraction in vitro; however, in the presence of 1 mM reduced glutathione, [3H]AVP was degraded by both preparations. Tritium 103-105 arginine vasopressin Homo sapiens 106-109 3425722-4 1987 Following microinfusion of [3H]AVP into proximal tubules, 15.7% of the label was absorbed. Tritium 28-30 arginine vasopressin Homo sapiens 31-34 3425722-5 1987 Five and fifteen minutes after infusion of [3H]AVP, sequestration of total label in proximal tubules was 4.5 and 2.1%, respectively, and quantitative electron microscope autoradiography revealed accumulation of grains over apical endocytic vacuoles and lysosomes consistent with endocytic uptake and rapid lysosomal degradation of AVP and/or a large metabolite. Tritium 44-46 arginine vasopressin Homo sapiens 47-50 3425722-5 1987 Five and fifteen minutes after infusion of [3H]AVP, sequestration of total label in proximal tubules was 4.5 and 2.1%, respectively, and quantitative electron microscope autoradiography revealed accumulation of grains over apical endocytic vacuoles and lysosomes consistent with endocytic uptake and rapid lysosomal degradation of AVP and/or a large metabolite. Tritium 44-46 arginine vasopressin Homo sapiens 331-334 2981085-4 1985 Consistent with its high uterotonic potency in nonpregnant uteri, arginine vasopressin was as effective as oxytocin in inhibiting [3H]oxytocin binding to corpus and fundus membrane preparations. Tritium 131-133 arginine vasopressin Homo sapiens 75-86 3769872-7 1986 On the other hand, PTH-(1-34), human PRL, and lysine vasopressin all activate mononuclear leukocytes, as determined by [3H]thymidine incorporation. Tritium 120-122 arginine vasopressin Homo sapiens 53-64 3019148-4 1986 Aliquots of a broken epithelial cell preparation, derived from bladders that had been exposed to the analogue in the presence of UV light, bound less tritium-labeled vasopressin ([3H]AVP) than control aliquots that had been exposed to the analogue in the absence of UV irradiation or irradiated in the absence of the analogue. Tritium 150-157 arginine vasopressin Homo sapiens 166-177 3006506-1 1986 Binding of tritium-labeled vasopressin [( 3H]AVP) to a broken epithelial cell preparation of the toad"s urinary bladder has been related to hormonal action on water and urea transport across the intact tissue. Tritium 11-18 arginine vasopressin Homo sapiens 27-38 3006506-1 1986 Binding of tritium-labeled vasopressin [( 3H]AVP) to a broken epithelial cell preparation of the toad"s urinary bladder has been related to hormonal action on water and urea transport across the intact tissue. Tritium 11-18 arginine vasopressin Homo sapiens 45-48 2947237-6 1986 Lysine vasopressin and the V1 antagonist [1-deaminopenicillamine, 2-(O-methyl)tyrosine]Arg8-vasopressin compete with high affinity with [3H]AVP binding, whereas the V2 agonist [1-deamino,4-valine]D-Arg8-vasopressin (dVDAVP) is 110 times less potent than AVP. Tritium 137-139 arginine vasopressin Homo sapiens 7-18 2947237-6 1986 Lysine vasopressin and the V1 antagonist [1-deaminopenicillamine, 2-(O-methyl)tyrosine]Arg8-vasopressin compete with high affinity with [3H]AVP binding, whereas the V2 agonist [1-deamino,4-valine]D-Arg8-vasopressin (dVDAVP) is 110 times less potent than AVP. Tritium 137-139 arginine vasopressin Homo sapiens 92-103 2947237-6 1986 Lysine vasopressin and the V1 antagonist [1-deaminopenicillamine, 2-(O-methyl)tyrosine]Arg8-vasopressin compete with high affinity with [3H]AVP binding, whereas the V2 agonist [1-deamino,4-valine]D-Arg8-vasopressin (dVDAVP) is 110 times less potent than AVP. Tritium 137-139 arginine vasopressin Homo sapiens 140-143 2947237-6 1986 Lysine vasopressin and the V1 antagonist [1-deaminopenicillamine, 2-(O-methyl)tyrosine]Arg8-vasopressin compete with high affinity with [3H]AVP binding, whereas the V2 agonist [1-deamino,4-valine]D-Arg8-vasopressin (dVDAVP) is 110 times less potent than AVP. Tritium 137-139 arginine vasopressin Homo sapiens 92-103 2947237-6 1986 Lysine vasopressin and the V1 antagonist [1-deaminopenicillamine, 2-(O-methyl)tyrosine]Arg8-vasopressin compete with high affinity with [3H]AVP binding, whereas the V2 agonist [1-deamino,4-valine]D-Arg8-vasopressin (dVDAVP) is 110 times less potent than AVP. Tritium 137-139 arginine vasopressin Homo sapiens 219-222 3026353-3 1986 When [3H]inositol-labelled hepatocytes were stimulated with 0.23 microM-vasopressin in the presence of 10 mM-Li+, there was an accumulation of radioactivity in InsP, InsP2 and InsP3 but not in Ins or the two unidentified compounds. Tritium 6-8 arginine vasopressin Homo sapiens 72-83 4636728-0 1972 Tritium labelling of 8-lysine vasopressin and its purification by affinity chromatography on sepharose bound neurophysins. Tritium 0-7 arginine vasopressin Homo sapiens 30-41 6730860-5 1984 Vasopressin decreased the incorporation of [3H]proline slightly but the action of this hormone was significantly less than that of oxytocin. Tritium 43-46 arginine vasopressin Homo sapiens 0-11 189620-5 1977 This effect of vasopressin was specific for protein kinase since activity of lactate dehydrogenase or a specific [3H]colchicine-binding activity was not affected, and the decrease in the protein kinase was not due to the accumulation of a heat-stable protein kinase inhibitor. Tritium 114-116 arginine vasopressin Homo sapiens 15-26 12195123-6 2002 RESULTS: YM471 potently and concentration-dependently inhibited the specific binding of [ 3H]AVP to V1A receptors on VSMCs, exhibiting an inhibition constant (Ki ) of 0.35 nmol/l. Tritium 90-92 arginine vasopressin Homo sapiens 93-96 5801808-0 1969 Purification and stability of specifically tritium labelled lysine vasopressin (tyrosine2-3-T-lysine8-sopressin). Tritium 43-50 arginine vasopressin Homo sapiens 67-78 4930026-0 1971 Some metabolites of specifically tritium labelled lysine-vasopressin: identification by thin-layer chromatography and determination by the liquid scintillation technique. Tritium 34-41 arginine vasopressin Homo sapiens 58-69 29079359-8 2018 Copeptin concentrations increased to maximal levels immediately after the race and were normalized in >90% after 3h. Tritium 116-118 arginine vasopressin Homo sapiens 0-8 15613460-10 2004 In [3H]thymidine-uptake experiments, we subsequently observed that PLC, Ca2+, PKC and ERK1/2 are absolutely required for the OT- and VP-stimulated SCLC cellular growth process. Tritium 4-6 arginine vasopressin Homo sapiens 133-135 9929562-3 1999 Adding AVP to CHO cells transfected with human V1A or V1B cDNA significantly and concentration-dependently induced activation of MAP kinase and increased DNA synthesis, as measured by [3H]thymidine incorporation. Tritium 185-187 arginine vasopressin Homo sapiens 7-10 9630655-17 1998 Results of these studies demonstrate that exposure of cortical neurons to the selective V1 vasopressin receptor agonist, [Phe2,Orn8]-vasotocin, (V1 agonist) induced a significant accumulation of [3H]inositol-1-phosphate ([3H]IP1). Tritium 196-198 arginine vasopressin Homo sapiens 91-102 7895079-3 1994 Results of this investigation demonstrate that exposure of cultured hippocampal neurons prelabeled with [3H]myo-inositol to vasopressin induced a significant accumulation of [3H]inositol-1-phosphate ([3H]IP1). Tritium 105-107 arginine vasopressin Homo sapiens 124-135 9247484-5 1997 AVP-specific binding was measured with [3H]AVP. Tritium 40-42 arginine vasopressin Homo sapiens 0-3 9247484-5 1997 AVP-specific binding was measured with [3H]AVP. Tritium 40-42 arginine vasopressin Homo sapiens 43-46 7895079-8 1994 Investigation of the effect of closely related peptides on [3H]IP1 accumulation indicated that the vasopressin metabolite peptide AVP4-9 and oxytocin significantly increased [3H]IP1 accumulation whereas the vasopressin metabolite peptide AVP4-8 did not. Tritium 60-62 arginine vasopressin Homo sapiens 99-110 7895079-8 1994 Investigation of the effect of closely related peptides on [3H]IP1 accumulation indicated that the vasopressin metabolite peptide AVP4-9 and oxytocin significantly increased [3H]IP1 accumulation whereas the vasopressin metabolite peptide AVP4-8 did not. Tritium 175-177 arginine vasopressin Homo sapiens 99-110 7895079-9 1994 AVP4-9 and oxytocin induced [3H]IP1 accumulation were blocked by the V1 vasopressin receptor antagonist d(CH2)5[Tyr(Me)2]-vasopressin. Tritium 29-31 arginine vasopressin Homo sapiens 72-83 7895079-9 1994 AVP4-9 and oxytocin induced [3H]IP1 accumulation were blocked by the V1 vasopressin receptor antagonist d(CH2)5[Tyr(Me)2]-vasopressin. Tritium 29-31 arginine vasopressin Homo sapiens 122-133 7834378-8 1994 Investigation of the effect of closely related peptides on [3H]IP1 accumulation indicated that the vasopressin metabolite peptide AVP4-9 and oxytocin significantly increased [3H]IP1 accumulation whereas the vasopressin metabolite peptide AVP4-8 did not. Tritium 175-177 arginine vasopressin Homo sapiens 99-110 7834378-9 1994 AVP4-9 and oxytocin induced [3H]IP1 accumulation were blocked by the V1 vasopressin receptor antagonist d(CH2)5[Tyr(Me)2]-vasopressin. Tritium 29-31 arginine vasopressin Homo sapiens 72-83 7834378-9 1994 AVP4-9 and oxytocin induced [3H]IP1 accumulation were blocked by the V1 vasopressin receptor antagonist d(CH2)5[Tyr(Me)2]-vasopressin. Tritium 29-31 arginine vasopressin Homo sapiens 122-133 8498489-2 1993 In purified platelet membranes, high-affinity specific binding of [3H]AVP but not that of the V1 vascular antagonist [3H]d(CH2)5Tyr(Me)AVP was modulated by guanosine 5"-O-(3-thiotriphosphate) or sodium fluoride both in the presence and absence of MgCl2. Tritium 67-69 arginine vasopressin Homo sapiens 70-73 7834378-3 1994 Results of this investigation demonstrate that exposure of cultured hippocampal neurons prelabeled with [3H]myo-inositol to vasopressin induced a significant accumulation of [3H]inositol-1-phosphate ([3H]IP1). Tritium 105-107 arginine vasopressin Homo sapiens 124-135 7834378-8 1994 Investigation of the effect of closely related peptides on [3H]IP1 accumulation indicated that the vasopressin metabolite peptide AVP4-9 and oxytocin significantly increased [3H]IP1 accumulation whereas the vasopressin metabolite peptide AVP4-8 did not. Tritium 60-62 arginine vasopressin Homo sapiens 99-110 1330154-4 1992 Vasopressin ([Arg8]-VP) and a number of related analogues stimulated the accumulation of [3H]-IP and [3H]-PtdBuOH with similar EC50 values, generating the same rank order of potency for each response (Arg8-VP = vasotocin = Lys8-VP much greater than oxytocin). Tritium 90-92 arginine vasopressin Homo sapiens 0-11 1330154-8 1992 The onset of vasopressin-stimulated inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) mass formation preceded [3H]-PtdBuOH accumulation indicating that PtdCh hydrolysis was activated subsequent to PtdIns(4,5)P2 breakdown. Tritium 105-107 arginine vasopressin Homo sapiens 13-24 1330154-11 1992 Preincubation with the PKC inhibitor Ro-31-8220 abolished both TPA- and vasopressin-stimulated [3H]-PtdBuOH, suggesting that the intermediate activation of protein kinase C is involved in the regulation of PLD by vasopressin. Tritium 96-98 arginine vasopressin Homo sapiens 72-83 1330154-11 1992 Preincubation with the PKC inhibitor Ro-31-8220 abolished both TPA- and vasopressin-stimulated [3H]-PtdBuOH, suggesting that the intermediate activation of protein kinase C is involved in the regulation of PLD by vasopressin. Tritium 96-98 arginine vasopressin Homo sapiens 213-224 1330154-14 1992 Preincubation of the cells with EGTA, verapamil, or the receptor-operated calcium channel antagonist, SK&F 96365, reduced vasopressin-stimulated [3H]-PtdBuOH accumulation by approximately 30%, suggesting that influx of calcium has a significant role to play in the regulation of vasopressinstimulated PLD activity. Tritium 150-152 arginine vasopressin Homo sapiens 126-137 1330154-4 1992 Vasopressin ([Arg8]-VP) and a number of related analogues stimulated the accumulation of [3H]-IP and [3H]-PtdBuOH with similar EC50 values, generating the same rank order of potency for each response (Arg8-VP = vasotocin = Lys8-VP much greater than oxytocin). Tritium 102-104 arginine vasopressin Homo sapiens 0-11 1330154-6 1992 Inhibition of vasopressin-stimulated [3H]-IP and [3H]-PtdBuOH accumulation by the V1a receptor antagonists, Des-Gly9[beta-mercapto-beta,beta,-cyclopentamethylene propionyl, O-Et-Tyr2,Val4,Arg8]-vasopressin generated similar IC50 values suggesting that both these responses are mediated through the activation of a single V1a receptor subtype. Tritium 38-40 arginine vasopressin Homo sapiens 14-25 1330154-6 1992 Inhibition of vasopressin-stimulated [3H]-IP and [3H]-PtdBuOH accumulation by the V1a receptor antagonists, Des-Gly9[beta-mercapto-beta,beta,-cyclopentamethylene propionyl, O-Et-Tyr2,Val4,Arg8]-vasopressin generated similar IC50 values suggesting that both these responses are mediated through the activation of a single V1a receptor subtype. Tritium 50-52 arginine vasopressin Homo sapiens 14-25 1396896-1 1992 The binding of tritium-labelled arginine vasopressin to human platelet vasopressin receptors was investigated in patients with congenital nephrogenic diabetes insipidus. Tritium 15-22 arginine vasopressin Homo sapiens 41-52 1396896-1 1992 The binding of tritium-labelled arginine vasopressin to human platelet vasopressin receptors was investigated in patients with congenital nephrogenic diabetes insipidus. Tritium 15-22 arginine vasopressin Homo sapiens 71-82 2280671-6 1990 The phosphatidylcholine in A-10 cells can be preferentially radiolabeled with [3H]myristic acid; subsequent treatment with vasopressin stimulates a rapid increase in 3H-labeled phosphatidate (approximately 4 X control values at 3 min), and after a short lag, 3H-labeled diacylglycerol rises and reaches maximal levels at 10 min (approximately 2 X control values). Tritium 79-81 arginine vasopressin Homo sapiens 123-134 1323272-3 1992 Vasopressin stimulated sustained accumulation of total [3H]inositol phosphates ([3H]IP) in the presence of Li+; however, this was significantly decreased by adding a vasopressin-receptor antagonist at different times after initial stimulation. Tritium 56-58 arginine vasopressin Homo sapiens 0-11 1323272-3 1992 Vasopressin stimulated sustained accumulation of total [3H]inositol phosphates ([3H]IP) in the presence of Li+; however, this was significantly decreased by adding a vasopressin-receptor antagonist at different times after initial stimulation. Tritium 56-58 arginine vasopressin Homo sapiens 166-177 1323272-12 1992 This coincided with an enhancement of vasopressin-stimulated [3H]IP accumulation. Tritium 62-64 arginine vasopressin Homo sapiens 38-49 1323272-13 1992 In cells exposed to the V1a-receptor antagonist 5 min after addition of vasopressin, subsequent DAG formation was significantly decreased, indicating that sustained formation of DAG, like [3H]IP accumulation, was dependent on continual agonist receptor activation. Tritium 189-191 arginine vasopressin Homo sapiens 72-83 2280671-6 1990 The phosphatidylcholine in A-10 cells can be preferentially radiolabeled with [3H]myristic acid; subsequent treatment with vasopressin stimulates a rapid increase in 3H-labeled phosphatidate (approximately 4 X control values at 3 min), and after a short lag, 3H-labeled diacylglycerol rises and reaches maximal levels at 10 min (approximately 2 X control values). Tritium 166-168 arginine vasopressin Homo sapiens 123-134